Technology Overview:

Innovative Biosensors’ clinical diagnostic system is based on the CANARY® (Cellular Analysis and Notification of Antigen Risks and Yields) technology, a revolutionary diagnostic technology developed by the scientists at Massachusetts Institute of Technology and recently published in Science. This platform delivers extremely rapid detection of pathogens at previously unseen levels of sensitivity and specificity. The technology is being developed with a standalone instrument and a test menu to address the global infectious disease market.

FIG. 1 — CANARY® Sensor Concept

The patented, self-contained system consists of engineered biosensors expressing membrane bound, pathogen-specific antibodies and a calcium sensitive bioluminescent molecule. Cross-linking of the antibodies by even minute amounts of the specific pathogen leads to elevation of intracellular calcium and light emission (FIG.1). The amplified light output is detected using an easy-to-use luminometer.

Click here to view assay operation using the CANARY® technology

Related Publications:

Rider et al. (2003). B Cell-based sensor for rapid identification of pathogens. Science, 301:213-215.

Rowe et al. (1999). Array biosensor for simultaneous identification of bacterial, viral, and protein analytes. Anal. Chem., 71: 3846-3852.

Belgrader et al. (2003). A reusable flow-through polymerase chain reaction instrument for the continuous monitoring of infectious biological agents. Anal. Chem., 75: 3446-3450.

Pourahmadi et al. (2000). Toward a rapid, integrated, and fully automated DNA diagnostic assay for chlamydia trachomatis and neisseria gonorrhea Clin. Chem., 46: 1511-1513.